Canada markets closed

Algernon Pharmaceuticals Inc. (AGN.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.2400+0.0050 (+2.13%)
At close: 3:38PM EST

Algernon Pharmaceuticals Inc.

700 West Pender Street
Suite 915
Vancouver, BC V6C 1G8
604 646 1553

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher J. MoreauCEO & Director108kN/A1965
Mr. Michael S. M. Sadhra CA, CPACFO & Director48kN/A1969
Mr. Mark WilliamsChief Science Officer138.49kN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non–alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Corporate Governance

Algernon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.